Global Hemophilia Market Report: 2016 Edition – New Report by Koncept Analytics

The report provides a comprehensive study of global hemophilia market and also major regional markets.

Hemophilia refers to a group of inherited genetic conditions that damages the body's capability to control blood clotting, which controls bleeding when a blood vessel breaks. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. Depending upon the clotting factor deficiency, there are several types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.

The market is anticipated to be driven by key factors such as increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some significant progresses of this industry include increasing adoption of prophylaxis therapy, introduction of extended half-life products etc. However, the growth of respective industry is faced by challenges such as high cost of treatments and high reluctance by patients to switch to new treatments/products.

The research report, “Global Hemophilia Market Report: 2016 Edition” by Koncept Analytics provides a wide-ranging research and comprehensive analysis of the global hemophilia industry, along with a detailed study of its various regional markets such as the US the European market. It also discusses the major trends of the industry such as the development of gene therapy.

The industry is highly competitive comprising a number of large companies including the Bayer Group, Shire Plc, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players including companies’ important growth strategies, business overview and financial position are also conferred for reference. The report is a must read for all those willing to invest in this area and trying to assess potential opportunities.

List of Charts

Types of Hemophilia
Global Hemophilia Prevalence (2015)
Global Hemophilia Diagnosis and Treatment Ratio (2015)
Global Hemophilia Market Revenue (2015E-2020F)
Global Hemophilia Revenue Share by Category (2015E)
Global Hemophilia Revenue Share by Category –Forecast (2020)
Global FVIII Demand by Volume (2011-2015E)
Global FVIII Demand by Category - Volume (2015E-2017E)
Global Supply Capacity of Recombinant FVIII – Actual (2011-2015E)
Global Supply Capacity of Recombinant FVIII – Forecast (2016F-2017F)
Global Hemophilia A Market Revenue (2015E-2020F)
Global Hemophilia A Revenue Share by Category (2015E)
Global Hemophilia B Market Revenue (2015E-2020F)
Global Hemophilia with Inhibitors Market Revenue (2015E-2020F)
The US Hemophilia Patients Treated per Year (2013-2020F)
The US Hemophilia Market Revenue (2013-2015E)
The US Hemophilia Market Revenue – Forecast (2016F-2020F)
The US Hemophilia A Patients Treated per Year (2013-2020F)
The US Hemophilia A Market Revenue (2013-2020F)
The US Hemophilia B Patients Treated per Year (2013-2020F)
The US Hemophilia B Market Revenue (2013-2020F)
The US Hemophilia with Inhibitors Patients Treated per Year (2013-2020F)
The US Hemophilia with Inhibitors Market Revenue (2013-2020F)
The US Von Willebrand Factor Market Revenue (2013-2020F)
Europe Hemophilia Patients (2014-2020F)
Europe Hemophilia A Patients (2014-2020F)
Europe Hemophilia A Patients by Severity (2015E)
Europe Hemophilia A Therapy by Severity (2015E)
Europe Hemophilia B Patients (2015E-2020F)
Europe Hemophilia B Patients by Severity (2015E)
Europe Hemophilia B Therapy by Severity (2015E)
Penetration of Recombinant FVIII (2014)
Global Healthcare Expenditure Per Capita (2009-2014E)
Global Per Capita Usage of FVIII by Income Groups (2014)
Prophylaxis Therapy Usage by Category (2015E)
Global Hemophilia Market Share (2015E)
Global Hemophilia A Market Share (2015E)
Market Capitalization Comparison (2015)
Gross Profit Margin Comparison (2015)
Revenue Share by Product Category, Shire PLC (2015)
Revenue and Net Income, Shire PLC (2011-2015)
Revenue Share by Business Segments, Bayer Group (2015)
Revenue and Net Income, BAYER (2011-2015)
Revenue Share by Business Segments, Novo Nordisk (2015)
Revenue and Net Income, Novo Nordisk (2011-2015)
Revenue Share by Business Segments, Pfizer Inc. (2015)
Revenue and Net Income, Pfizer (2011-2015)

List of Tables

Gene Therapy Products under Development (2015)
Extended Half-Life Products under Development (2015)

For more Information:
http://www.konceptanalytics.com/Researchreport/global-hemophilia-market-report-2016-edition-3278.aspx

Koncept Analytics
Vikas Gupta
(Business Development Manager)
FFCS-36, Ansal Plaza
Vaishali, Ghaziabad
U.P - 201010
Tele: +91-120-4130959
Mobile: +91-9811715635
Mail ID – vikas@konceptanalytics.com

Koncept Analytics is a market research company. We are in the field of Market Research from last 10 Years. We do research in telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, food & beverages and media sectors. For more information:
konceptanalytics.com

Koncept Analytics is a market research company. We are in the field of Market Research from last 10 Years. We do research in telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, food & beverages and media sectors. For more information:
http://www.konceptanalytics.com

Koncept Analytics
Vikas Gupta
(Business Development Manager)
http://www.konceptanalytics.com/Researchreport/global-hemophilia-market-report-2016-edition-3278.aspx

FFCS-36, Ansal Plaza
Vaishali, Ghaziabad
U.P - 201010
Tele: +91-120-4130959
Mobile: +91-9811715635
Mail ID – vikas@konceptanalytics.com

This release was published on openPR.